Cue Biopharma Inc
NASDAQ:CUE 4:00:00 PM EDT
| Market Cap (Intraday) | 29.09M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.62 |
| 50-Day MA | $0.74 |
| 200-Day MA | $1.76 |
Cue Biopharma Inc Stock, NASDAQ:CUE
40 Guest Street, Boston, Massachusetts 02135
United States of America
Phone: +1.617.949.2680
Number of Employees: 53
Description
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.